sur TRANSGENE (EPA:TNG)
Transgene consolidates its balance sheet thanks to the conversion of part of the advance into shares
Transgene, a biotechnology company specializing in cancer immunotherapies, announces the conversion of 32,999,999.57 euros of debt into shares. This operation, supported by its majority shareholder TSGH, a subsidiary of Institut Mérieux, increases TSGH's stake in Transgene's capital from 59.7% to 69.1%.
In September 2023, Transgene signed a current account advance agreement with TSGH for an initial amount of 36 million euros, increased to 66 million in March 2024. To date, 35.6 million euros have been fired. This conversion makes it possible to reduce the company's net debt.
The gross proceeds of the operation amount to 32,999,999.57 euros, intended to repay this advance. Transgene expects to have the necessary liquidity until the fourth quarter of 2025. This increased financial capacity will allow the company to continue developing its innovative immunotherapies.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de TRANSGENE